Correia Augusto Ferreira, Oliveira Carolina Gomes Cavalcanti de, Oliveira Dinaldo Cavalcanti de, Pereira Michelly Cristina, Carvalho Flavio Alisson, Martins Estevão Campos Carvalho, Oliveira Dinaldo Cavalcanti de
Internal Medicine Department, Cardiology Division, Federal University of Pernambuco, Recife 50670-901, Brazil.
Cardiology Emergency Room of Pernambuco, University of Pernambuco, Recife 52010-010, Brazil.
J Clin Med. 2024 Aug 23;13(17):4971. doi: 10.3390/jcm13174971.
Acute coronary syndrome (ACS) represents an important clinical manifestation of coronary artery disease (CAD) and is characterized by a particularly poor prognosis. Myocardial reperfusion through primary percutaneous coronary intervention (PPCI) is imperative in the event of acute ST elevation myocardial infarction (STEMI). Interleukin-22 (IL-22) regulates immune and inflammatory responses. This interleukin has been described in the scenario of the CAD, but there are no data in patients with STEMI undergoing PPCI. : The goals of this study were to investigate the differences in circulating IL-22 levels between patients with STEMI undergoing PPCI and healthy controls and to determine whether these differences were associated with the culprit coronary artery, door-to-balloon time (DBT), final angiographic result, CAD classification, and presence of diabetes mellitus (DM). : A total of 280 participants were recruited, comprising 210 STEMI cases and 70 healthy controls. Participants underwent clinical and angiographic evaluations, and serum IL-22 levels were measured using an enzyme-linked immunosorbent assay (ELISA). Data analysis was performed using the Mann-Whitney and Fisher tests, with < 0.05 indicating significance. : Serum IL-22 levels were lower in cases (149.63, 84.99-294.56) than in the controls (482.67, 344.33-641.00); < 0.001. Lower IL-22 levels were associated with the right coronary artery (RCA) (144.57, 70.84-242.43; 146.00, 63.60-279.67; 191.71, 121.80-388.97); = 0.033. IL-22 was lower with shorter DBT (≤60 min, 106.00, 49.60-171.71; >60 min, 153.00, 88.86-313.60); = 0.043. : IL-22 levels were significantly lower in patients with STEMI than in healthy controls.
急性冠状动脉综合征（ACS）是冠状动脉疾病（CAD）的一种重要临床表现，其预后特别差。对于急性ST段抬高型心肌梗死（STEMI）患者，通过直接经皮冠状动脉介入治疗（PPCI）实现心肌再灌注至关重要。白细胞介素-22（IL-22）调节免疫和炎症反应。在CAD的情况下已对这种白细胞介素进行了描述，但在接受PPCI的STEMI患者中尚无相关数据。本研究的目的是调查接受PPCI的STEMI患者与健康对照者循环IL-22水平的差异，并确定这些差异是否与罪犯冠状动脉、门球时间（DBT）、最终血管造影结果、CAD分类以及糖尿病（DM）的存在有关。总共招募了280名参与者，包括210例STEMI病例和70名健康对照者。参与者接受了临床和血管造影评估，并使用酶联免疫吸附测定（ELISA）测量血清IL-22水平。使用Mann-Whitney和Fisher检验进行数据分析，P<0.05表示有统计学意义。病例组血清IL-22水平（149.63，84.99 - 294.56）低于对照组（482.67，344.33 - 641.00）；P<0.001。较低的IL-22水平与右冠状动脉（RCA）相关（144.57，70.84 - 242.43；146.00，63.60 - 279.67；191.71，121.80 - 388.97）；P = 0.033。DBT较短时IL-22水平较低（≤60分钟，106.00，49.60 - 171.71；>60分钟，153.00，88.86 - 313.60）；P = 0.043。STEMI患者的IL-22水平显著低于健康对照者。
